Prevention of Recurrent Venous Thromboembolism (PREVENT)

This study has been completed.

First Received: October 27, 1999 Last Updated: September 12, 2005 History of Changes

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00000614

Purpose

A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.

Condition	Intervention	Phase
Cardiovascular Diseases Heart Diseases Peripheral Vascular Diseases Thromboembolism Vascular Diseases Venous Thromboembolism	Drug: warfarin	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control

Resource links provided by NLM:

MedlinePlus related topics: Blood Thinners Heart Diseases Peripheral Arterial Disease Vascular Diseases

Drug Information available for: Warfarin

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:	September 1998
Estimated Study Completion Date:	August 2004

Show Detailed Description

Eligibility

Ages Eligible for Study:	30 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with venous thromboembolism, including patients with factor V Leiden. Patients had completed prescribed anticoagulation therapy within the last two years before the trial and were not currently on anticoagulation therapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000614

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigator:

Robert Glynn

Brigham and Women's Hospital

More Information

Publications:

Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med. 1998;3(1):67-73. Review.

Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10;348(15):1425-34. Epub 2003 Feb 24.

Schafer AI. Warfarin for venous thromboembolism - walking the dosing tightrope. N Engl J Med. 2003 Apr 10;348(15):1478-80. Epub 2003 Feb 24. No abstract available.

Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001 Jan;37(1):215-8.

Sick PB, Brosteanu O, Ulrich M, Thiele H, Niebauer J, Busch I, Schuler G. Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Am Heart J. 2005 Apr;149(4):681-8.

Study ID Numbers:	117
Study First Received:	October 27, 1999
Last Updated:	September 12, 2005
ClinicalTrials.gov Identifier:	NCT00000614 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Embolism and Thrombosis
Peripheral Vascular Diseases
Heart Diseases
Embolism
Vascular Diseases

Warfarin
Venous Thromboembolism
Thrombosis
Recurrence
Thromboembolism

Additional relevant MeSH terms:

Embolism and Thrombosis
Peripheral Vascular Diseases
Heart Diseases
Vascular Diseases

Cardiovascular Diseases
Venous Thromboembolism
Thrombosis
Thromboembolism

ClinicalTrials.gov processed this record on July 02, 2009